首页> 美国卫生研究院文献>Journal of Public Health in Africa >Economic Evaluations of Pharmacogenetic Approaches in Infectious Diseases: A Review of Current Approaches and Evaluation of Critical Aspects Affecting their Quality
【2h】

Economic Evaluations of Pharmacogenetic Approaches in Infectious Diseases: A Review of Current Approaches and Evaluation of Critical Aspects Affecting their Quality

机译:传染病药物遗传学方法的经济评估:当前方法的综述和影响其质量的关键方面的评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Pharmacogenetics holds great potential for improving the effectiveness of treatment modalities in infectious diseases by taking into account the genetic determinants of both the host and infectious agents’ individuality. Better utilization of resources and improved therapeutic efficiency are the expected outcomes of personalized medicine using pharmacogenetic and pharmacogenomics information made available by technological advances. However, there has been growing concern in the clinical community regarding the evaluation of the true benefits of these approaches. This perception is partly due to the limited number and perceived poor quality of economic evaluations in this field, and initiatives aimed at harmonizing and communicating strategies improving the quality of these studies and their acceptance by the clinical community are greatly needed. This paper reviews current literature of economic evaluations of pharmacogenetics interventions guiding pharmacotherapy in infectious diseases. PubMed and the NHS Centre for Reviews and Dissemination databases were searched using a combination of five broad research terms related to pharmacogenetic approaches, and papers relative to economic evaluations of pharmacogenetic interventions in infectious diseases retained for further analysis. Using these criteria, a total of 14 papers were included in this review. The area of economic evaluation of pharmacogenetic interventions in infectious diseases remains understudied and would benefit from greater harmonization. The main weaknesses of evaluations reviewed in this paper seem to be represented by poor evidence of pharmacogenetic marker validation, inconsistencies in the selection of costs and utility included in the economic models and the choice of sensitivity analysis. All these factors limit the overall transparency of the studies, greater acceptance of their results and applicability to diverse and possibly resourcelimited environments where these approaches could be expected to have the greater impact.
机译:通过考虑宿主和传染原个体的遗传决定因素,药物遗传学在改善传染病治疗方式的有效性方面具有巨大潜力。利用技术进步提供的药物遗传学和药物基因组学信息,更好地利用资源和提高治疗效率是个性化药物的预期结果。然而,在临床社区中,关于这些方法的真正益处的评估越来越引起人们的关注。这种看法部分是由于该领域中经济评估的数量有限和质量低下,因此迫切需要采取旨在协调和交流提高这些研究质量并被临床界接受的策略的举措。本文综述了有关指导感染性药物治疗的药物遗传学干预措施经济评价的最新文献。使用五个与药物遗传学方法相关的广泛研究术语的组合,搜索了PubMed和NHS审查和传播中心数据库,并保留了与药物遗传学干预措施有关的传染病经济评估的相关论文,以供进一步分析。使用这些标准,本评价总共包括14篇论文。对传染病药物遗传学干预措施的经济评价领域仍未得到充分研究,并将受益于更大程度的协调。本文综述的评估的主要弱点似乎表现为药物遗传标志物验证的证据不充分,经济模型中成本和效用的选择不一致以及敏感性分析的选择。所有这些因素都限制了研究的总体透明度,研究结果的接受程度以及在各种可能受到资源限制的环境中的适用性,在这些环境中这些方法有望产生更大的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号